Chromanone Compound Composition for Selective Multiple Myeloma Killing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple myeloma, a blood cancer caused by abnormal proliferation of plasma cells, are associated with significant side effects and drug resistance, necessitating the development of novel, side-effect-free small-molecule compounds with enhanced therapeutic efficacy.
Innovation Solution
Development of chromanone and phenylpropenone compounds represented by Formula (1), which exhibit selective killing effects on multiple myeloma cell lines and demonstrate significant therapeutic effects with reduced toxicity to normal hematopoietic stem cells, potentially synergistic with existing treatments like lenalidomide.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (melphalan, prednisone, thalidomide, lenalidomide, bortezomib) are used to treat multiple myeloma, then therapeutic effect is achieved, but side effects (pancytopenia, peripheral neuritis, emboli/thrombosis, secondary cancers) and drug resistance occur
Solution Approach 1:
The patent changes the chemical structure parameters by introducing a novel chromanone core structure with specific substituents (R1-C1-C3 alkyl, R2-hydrogen or substituted phenyl, R3-hydrogen, R4-substituted phenyl or heteroaryl) to create compounds with improved therapeutic profiles. This structural parameter change results in selective killing of multiple myeloma cells while preserving normal hematopoietic stem cells, thereby reducing side effects and overcoming drug resistance
Solution Approach 2:
The patent creates composite chemical structures by combining the chromanone core with various aromatic and heteroaromatic substituents (including pyridine, pyrimidine, triazine rings with nitrogen atoms). This composite structural approach enables the compounds to achieve both anticancer activity against multiple myeloma and selective toxicity sparing normal cells
2Reliability
If existing immunomodulators and proteasome inhibitors are used, then multiple myeloma treatment is achieved, but normal hematopoietic stem cells are destroyed or inhibited causing serious side effects
Solution Approach 1:
The patent applies local quality by designing compounds with specific functional groups positioned at particular locations on the chromanone core. The substituents at R1, R2, R3, and R4 positions create localized chemical properties that enable selective interaction with multiple myeloma cells through specific molecular targets, while normal hematopoietic stem cells are spared due to differences in their cellular targets or uptake mechanisms
Data Source
AI summary
The present invention provides a novel compound having a chromanone or its ring-opening form, phenylpropenone, as backbone and compositions for the preventing or treating multiple myeloma, comprising the same. The compounds of the invention exhibit significant killing effects against various multiple myeloma cell lines and show in vivo anti-cancer effects that exceed those of lenalidomide, a commercially available immunomodulator widely used in the treatment of multiple myeloma and myelodysplastic syndromes. In addition, the compounds of the invention exhibit a significant synergistic effect when co-administered with the thalidomide or its analog lenalidomide, and thus are useful as an efficient therapeutic agent or therapeutic aid agent composition for multiple myeloma which is an incurable disease.